Ipilimumab Biosimilar, Human IgG4 S228P Mutant | C050P.4S

Catalog No.	C050P.4S
Product Name	Ipilimumab Biosimilar, Human IgG4 S228P Mutant | C050P.4S
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	cytotoxic T-lymphocyte?associated antigen 4, cytotoxic T-lymphocyte antigen 4, CD152, CTLA4
Summary	Recombinant fully human IgG1 monoclonal antibody.
Source/Host	The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
Specificity/Sensitivity	The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Ipilimumab Biosimilar, Human IgG4 S228P Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Ipilimumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C055P

C050P.4S: Ipilimumab Biosimilar, Human IgG4 S228P Mutant

Recombinant fully human IgG1 monoclonal antibody.

Background

What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

Please remember our product information: Ipilimumab Biosimilar, Human IgG4 S228P Mutant: C050P.4S Syd Labs

No more offers for this product!